Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation

NCT06740786 is registered in ClinicalTrials.gov with Xu Liu as lead sponsor.

NCT NCT06740786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06740786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation
Lead sponsor
Xu Liu
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 10, 2024
Completion date
May 1, 2026
Enrollment
250 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af)